Exposure of K562 cells to anti-receptor monoclonal antibody OKT9 results in rapid redistribution and enhanced degradation of the transferrin receptor - PubMed (original) (raw)
Exposure of K562 cells to anti-receptor monoclonal antibody OKT9 results in rapid redistribution and enhanced degradation of the transferrin receptor
A M Weissman et al. J Cell Biol. 1986 Mar.
Abstract
When the human erythroleukemia cell line K562 is treated with OKT9, a monoclonal antibody against the transferrin receptor, effects on receptor dynamics and degradation ensue. The apparent half-life of the receptor is decreased by greater than 50% as a result of OKT9 treatment. The transferrin receptor is also rapidly redistributed in response to OKT9 such that a lower percentage of the cellular receptors are displayed on the cell surface. OKT9 treatment also leads to a decrease in the total number of receptors participating in the transferrin cycle for cellular iron uptake. The reduction in iron uptake that results from the loss of receptors from the cycle leads to enhanced biosynthesis of the receptor. Receptors with bound OKT9 continue to participate in multiple cycles of iron uptake. However, OKT9 treatment appears to result in a relatively small increase per cycle in the departure of receptors from participation in iron uptake to a pathway leading to receptor degradation. Radiolabeled OKT9 is itself degraded by K562 cells and this degradation is inhibitable by leupeptin or chloroquine. In the presence of leupeptin, OKT9 treatment results in the enhanced intracellular accumulation of transferrin. Because the time involved in the transferrin cycle is shorter (12.5 min) than the normal half-life of the receptor (8 h), a small change in recycling efficiency caused by OKT9 treatment could account for the marked decrease in receptor half-life. In this paper the implications of these findings are discussed as they relate to systems in which receptor number is regulated by ligand.
Similar articles
- Regulation of intracellular iron distribution in K562 human erythroleukemia cells.
Mattia E, Josic D, Ashwell G, Klausner R, van Renswoude J. Mattia E, et al. J Biol Chem. 1986 Apr 5;261(10):4587-93. J Biol Chem. 1986. PMID: 3457008 - Structural features of the cell surface receptor for transferrin that is recognized by the monoclonal antibody OKT9.
Schneider C, Sutherland R, Newman R, Greaves M. Schneider C, et al. J Biol Chem. 1982 Jul 25;257(14):8516-22. J Biol Chem. 1982. PMID: 6282884 - Brain iron homeostasis.
Moos T. Moos T. Dan Med Bull. 2002 Nov;49(4):279-301. Dan Med Bull. 2002. PMID: 12553165 Review. - Transferrin receptor: its biological significance.
May WS Jr, Cuatrecasas P. May WS Jr, et al. J Membr Biol. 1985;88(3):205-15. doi: 10.1007/BF01871086. J Membr Biol. 1985. PMID: 3007762 Review. No abstract available.
Cited by
- Antibody-Based Inhibition of Pathogenic New World Hemorrhagic Fever Mammarenaviruses by Steric Occlusion of the Human Transferrin Receptor 1 Apical Domain.
Ferrero S, Flores MD, Short C, Vazquez CA, Clark LE, Ziegenbein J, Zink S, Fuentes D, Payes C, Batto MV, Collazo M, García CC, Abraham J, Cordo SM, Rodriguez JA, Helguera G. Ferrero S, et al. J Virol. 2021 Aug 10;95(17):e0186820. doi: 10.1128/JVI.01868-20. Epub 2021 Aug 10. J Virol. 2021. PMID: 34132574 Free PMC article. - A molecular sensor to quantify the localization of proteins, DNA and nanoparticles in cells.
FitzGerald LI, Aurelio L, Chen M, Yuen D, Rennick JJ, Graham B, Johnston APR. FitzGerald LI, et al. Nat Commun. 2020 Sep 8;11(1):4482. doi: 10.1038/s41467-020-18082-8. Nat Commun. 2020. PMID: 32901011 Free PMC article. - The influence of particle size and multiple apoprotein E-receptor interactions on the endocytic targeting of beta-VLDL in mouse peritoneal macrophages.
Tabas I, Myers JN, Innerarity TL, Xu XX, Arnold K, Boyles J, Maxfield FR. Tabas I, et al. J Cell Biol. 1991 Dec;115(6):1547-60. doi: 10.1083/jcb.115.6.1547. J Cell Biol. 1991. PMID: 1661729 Free PMC article. - Receptor Crosslinking: A General Method to Trigger Internalization and Lysosomal Targeting of Therapeutic Receptor:Ligand Complexes.
Moody PR, Sayers EJ, Magnusson JP, Alexander C, Borri P, Watson P, Jones AT. Moody PR, et al. Mol Ther. 2015 Dec;23(12):1888-98. doi: 10.1038/mt.2015.178. Epub 2015 Sep 28. Mol Ther. 2015. PMID: 26412588 Free PMC article. - Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferring receptor.
Suzuki S, Inoue K, Hongoh A, Hashimoto Y, Yamazoe Y. Suzuki S, et al. Br J Cancer. 1997;76(1):83-9. doi: 10.1038/bjc.1997.340. Br J Cancer. 1997. PMID: 9218737 Free PMC article.
References
- Proc Natl Acad Sci U S A. 1982 May;79(9):2822-6 - PubMed
- J Biol Chem. 1982 Jul 25;257(14):8516-22 - PubMed
- Proc Natl Acad Sci U S A. 1982 Oct;79(20):6186-90 - PubMed
- J Cell Biol. 1983 Jan;96(1):1-27 - PubMed
- J Biol Chem. 1983 Apr 25;258(8):4715-24 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources